Semaglutide with lower insulin glargine compared to higher insulin glargine alone for Type 2 Diabetes

Managing Type 2 Diabetes (T2D) often requires complex regimens, with insulin therapy being a cornerstone for many patients. However, high-dose insulin can lead to weight gain and increased risk of hypoglycemia, posing significant challenges for long-term adherence and overall patient well-being. Glucagon-Like Peptide-1 Receptor (GLP-1R) agonists like semaglutide offer a complementary mechanism by enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and promoting satiety, which can lead to improved glycemic control and weight loss. Investigating combinations of GLP-1R agonists with insulin, particularly strategies that allow for lower insulin doses, is crucial for optimizing T2D treatment and mitigating insulin-related side effects.

The SUSTAIN OPTIMIZE study is a clinical trial comparing two treatment arms in participants with Type 2 Diabetes. Participants will receive either semaglutide (once weekly) combined with a lower dose of insulin glargine, or a higher dose of insulin glargine alone. The study duration is approximately 47 weeks (11 months), involving 9 clinic visits, 15 phone/video calls, and 1 home visit. A key aspect of the protocol includes participants wearing a sensor for continuous blood sugar measurement (continuous glucose monitoring) during two 10-day periods to assess blood glucose control. The primary endpoint focuses on how well the study medicines control blood glucose levels.

This abstract describes the design and protocol of the SUSTAIN OPTIMIZE clinical trial, which aims to compare the efficacy of semaglutide combined with a lower dose of insulin glargine against a higher dose of insulin glargine monotherapy in patients with Type 2 Diabetes. As a study protocol description, it does not present any findings, numerical results, or statistical outcomes from the trial. The primary objective is to evaluate the impact of these treatment strategies on blood glucose levels. The study is designed to run for approximately 47 weeks, with participants undergoing continuous glucose monitoring during two distinct 10-day periods to gather comprehensive glycemic data.

No specific results, p-values, percentages, or fold-changes are available in this abstract, as it outlines the study's methodology rather than its completed findings.